Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer

Fig. 1

A CRPC related lncRNA LBCS associates with PCa clinical characteristics and good prognosis. a The differently expressed lncRNAs were validated by real time qPCR. b The expression of LBCS in LNCaP cells treated with either bicalutamide or androgen ablation at different point-in-time was detected by real time qPCR. c The expression of LBCS was detected in androgen dependent (LNCaP) and androgen independent (LNCaP-Bic, LNCaP-AI, 22Rv1) cell lines by real time qPCR. The results of real time qPCR were normalized to GAPDH and presented as the means ± SD of values obtained in three independent experiments. d Representative images of in situ hybridization (ISH) of LBCS expression (blue) in paraffin-embedded BPH (n = 32) and PCa (n = 130, 109 cases hormone sensitive and 21 cases of CRPC) prostate cancer tissue (Cohort 1). Red scale bars: 50 μm. e-h LBCS was detected between BPH and PCa, HSPC and CRPC, T1–2 and T3–4, Gleason Score (GS) 6–7 and 8–10 groups from cohort 1 by ISH. ISH of LBCS expression was quantified by the expression score (0–300). Patients with unavailable information was excluded for analysis. i-k LBCS was detected between BPH (n = 10) and PCa (n = 70), Gleason Score (GS) 6–7 and 8–10, T2 and T3–4 groups from cohort 2 by ISH. ISH of LBCS expression was quantified by the expression score (0–300). The whiskers indicate median ± interquartile in the plots. l The expression was LBCS was analyzed between 52 cases of BPH and 374 cases of PCa from TCGA. The whiskers indicate median ± interquartile in the plots. m-n The biochemical recurrence-free survival and progression-free survival rates of the 130 PCa patients from cohort 1 were compared in the LBCS-low and LBCS-high groups. Median H-Score was used as cut off value in the survival analysis. The patients with complete clinical and follow up information were adopted for survival, univariate and multivariate analysis. (See also Additional file 9: Figure S1) *p < 0.05, **p < 0.01

Back to article page